A Fresh Look at Disc Medicine's Valuation After Bitopertin NDA Submission and Positive Phase 2 Data [Yahoo! Finance]
Disc Medicine, Inc. (IRON)
Company Research
Source: Yahoo! Finance
Positive Phase 2 results support this filing. See our latest analysis for Disc Medicine. Disc Medicine's bold move on the bitopertin NDA builds on momentum from recent regulatory milestones and positive clinical data, fueling optimism around its rare disease portfolio. The stock's 1-year total shareholder return of 31% signals confidence is building, with investors watching closely for regulatory catalysts as shares consolidate around $67. If this wave of biotech innovation has you curious about what else is attracting attention, it could be the perfect moment to broaden your search and discover See the full list for free. With momentum building and shares trading at a notable discount to analyst targets, the real question for investors is whether Disc Medicine is an undervalued opportunity, or if the market is already pricing in the company's future growth potential. Price-to-Book Ratio of 3.8x: Is it justified? Disc Medicine trades at a price-to-book ratio of 3.8x, which
Show less
Read more
Impact Snapshot
Event Time:
IRON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRON alerts
High impacting Disc Medicine, Inc. news events
Weekly update
A roundup of the hottest topics
IRON
News
- Disc Medicine (NASDAQ:IRON) had its price target raised by analysts at Truist Financial Corporation from $86.00 to $114.00. They now have a "buy" rating on the stock.MarketBeat
- What Disc Medicine (IRON)'s Bitopertin Fast-Track Review and Rising R&D Spend Mean for Shareholders [Yahoo! Finance]Yahoo! Finance
- Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual MeetingGlobeNewswire
- Disc Medicine (NASDAQ:IRON) had its "buy" rating reaffirmed by analysts at Stifel Nicolaus. They now have a $125.00 price target on the stock.MarketBeat
IRON
Earnings
- 11/6/25 - Miss
IRON
Sec Filings
- 11/13/25 - Form 4
- 11/12/25 - Form 144
- 11/6/25 - Form 10-Q
- IRON's page on the SEC website